Merck Reports Results of Doravirine/Islatravir as Fixed Dose Combination in P-III Trials for the Treatment of HIV-1 Infection
Shots:
- The 2 P-III ILLUMINATE SWITCH A & B trials evaluate doravirine/islatravir (100/0.75mg- qd- PO) in a ratio (1:1) in 672 & 641 patients with HIV-1 who are virologically suppressed on different ART regimens or BIC/FTC/TAF
- Both the trials met its primary efficacy EPs i.e.- the proportion of patients with HIV-1 RNA levels ≥50 copies/mL demonstrated an antiviral efficacy b/w DOR/ISL & ART (ILLUMINATE SWITCH A) and DOR/ISL & BIC/FTC/TAF (ILLUMINATE SWITCH B) @ 48wks.- safety & tolerability are consistent with the previously reported P-II studies
- Doravirine is approved for HIV-1 in combination with other antiretrovirals as monothx. Pifeltro & Delstrigo. Islatravir is Merck’s NRTTIs inhibitor
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com